IMMUNOSIGN

Welcome to the Brand page for “IMMUNOSIGN”, which is offered here for Software for use in the clinical diagnosis, prognosis, monitoring, prediction of response to treatments and on-going evaluation, analysis and study of a cancer, tumor or equivalent medical condition, in the field of biology; application software in the nature of a mobile application for use in the clinical diagnosis, prognosis, monitoring, prediction of response to treatments and on-going evaluation, analysis and study of a cancer, tumor or equivalent medical condition in the field of biology;pharmaceutical products being chemical or biological preparations for medical and pharmaceutical use for use in vitro testing, for use in the clinical diagnostic, prognosis, monitoring, prediction of response to treatments and on-going evaluation, analysis and study of a cancer, tumor or equivalent medical condition; biological reagents for medical use for providing information on diagnostic or identification of biological systems; biological reagents for pharmaceutical use for providing information on diagnostics or identification of biological systems;medical analysis services; medical assistance; health services; medical therapeutic services; medical diagnostics, diagnostics in the field of medicine; genetic analysis services for medical purposes, analysis of a medical disorder, tumor, cancer or equivalent medical condition;medical apparatus and instruments for providing information on diagnostics or identification of biological systems, gene expression analysis and markers detection devices, medical testing devices and diagnostic apparatus for detecting, analyzing or assessing a cancer, tumor or equivalent medical condition; medical instruments for cell detection in the context of a cancer, tumor or equivalent medical condition;.

Its status is currently believed to be active. Its class is unavailable. “IMMUNOSIGN” is believed to be currently owned by “Veracyte”.